Skip to search formSkip to main contentSkip to account menu

RAF265

Known as: B-Raf/VEGFR-2 Inhibitor RAF265, RAF-265 
An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CHIR-265

Broader (2)

ImidazolesPyridines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Clinical evidence shows that dual inhibition of kinases as well angiogenesis provides ideal therapeutic option in the treatment… 
2015
2015
Discovery of RAF 265 : A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the… 
2014
2014
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways
SummaryPapillary thyroid cancer (PTC) is the most frequent thyroid cancer entity, accounting for 88 % of cases. It may… 
Highly Cited
2012
Highly Cited
2012
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Purpose: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for… 
Highly Cited
2011
Highly Cited
2011
Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
8508 Background: RAF265 is an oral small molecule inhibitor of mutant (mut) BRAFV600E(EC50= 0.14µM) and VEGFR2 (EC50 = 0.19µM… 
2011
2011
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
RAS mutations occur in more than 30% of all human cancers but efforts to directly target mutant RAS signaling as a cancer therapy… 
Highly Cited
2011
Highly Cited
2011
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Purpose: In thyroid cancer clinical trials, agents targeting VEGF receptors (VEGFR) and RET, among other kinases, have led to… 
2011
2011
SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration
Purpose We recently demonstrated increased frequency and growth potential of late outgrowth endothelial progenitor cells (OECs… 
2008
2008
Effectively targeting BRAF in melanoma: a formidable challenge
Since the finding of activating mutation of BRAF in cutaneous melanoma we have learned to appreciate the remarkable diversity of… 
2008
2008
[18F]Fluoroethylated VEGFR-2 tyrosine kinase inhibitors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)